Investors have filed a securities class action against Replimune Group, alleging the company misled the market by claiming its RP1 resubmission fully addressed FDA concerns, despite the FDA stating the trial was inadequate. The lawsuit highlights that the FDA's evidentiary standards for approval were not met, and the company failed to disclose specific regulatory objections, leading to a sharp 84% stock price drop after the FDA's rejection. The case seeks to represent shareholders who bought Replimune shares between October 2025 and April 2026, with a lead plaintiff application deadline of October 5, 2026. This lawsuit raises important questions about transparency in biotech regulatory communications and investor risk disclosure.
UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...
Chewy reported quarterly earnings of $0.36 per share, doubling analyst estimates of $0.18, with net income rising to $80.5 million from $62 million a year ago. Quarterly revenue reached $3.33 billion, slightly above expectations, marking a 7.3% incre...
AeroVironment, a leading drone maker, is set to report its Q3 earnings on September 9, 2026, with analysts expecting EPS between $0.22 and $0.25 and revenue near $452-$456 million. The company recently secured major contracts worth over $865 million ...
Bernstein has reduced the price target for Newmont Corporation to $144, reflecting challenges including a 13% drop in gold production and rising costs expected to reach $1,680 per ounce in 2026. Despite these issues, Newmont's stock gained 34.5% in A...
Barrick Mining maintains an 'Outperform' rating from Bernstein despite a lowered price target of $56.50, down from $61.00. The company reported an 11% increase in gold production in Q2 to 796,000 ounces, with further growth expected in the coming qua...
